AbCellera Biologics (ABCL) Total Current Liabilities (2020 - 2026)

AbCellera Biologics' Total Current Liabilities history runs 7 years deep, the most recent figure standing at $47.3 million for Q1 2026.

• Quarterly Total Current Liabilities fell 37.27% year-over-year to $47.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $47.3 million (down 37.27% YoY) and the FY2025 annual result came in at $64.3 million, down 16.06% from the prior year.
• Total Current Liabilities was $47.3 million for Q1 2026 at AbCellera Biologics, down from $64.3 million in the prior quarter.
• Across five years, Total Current Liabilities topped out at $221.1 million in Q2 2022 and bottomed at $47.3 million in Q1 2026.
• A 5-year average of $103.0 million and a median of $89.6 million in 2023 frame the typical range for Total Current Liabilities.
• Annual changes were most pronounced in 2022 — Total Current Liabilities surged 217.01% — and 2023, when it plunged 58.02%.
• AbCellera Biologics' Total Current Liabilities stood at $118.3 million in 2022, then grew by 0.59% to $119.0 million in 2023, then slumped by 35.63% to $76.6 million in 2024, then decreased by 16.06% to $64.3 million in 2025, then fell by 26.46% to $47.3 million in 2026.
• Business Quant data shows ABCL's Total Current Liabilities at $47.3 million in Q1 2026, $64.3 million in Q4 2025, and $68.8 million in Q3 2025.